Current approach to adjuvant therapy for breast cancer (a review)
The current approaches to therapy for breast cancer (BC) are based on whether the major markers, such as estrogen receptors, progesterone receptors, and HER2-receptors, are present or absent. Scientific update suggests that subdividing BC into more minor, but distinct subgroups will be continued and...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
PierFranco Conte [verfasserIn] Valentina Guarneri [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Russisch |
| Erschienen: |
2013 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Современная онкология - IP Habib O.N., 2019, 15(2013), 1, Seite 12-18 |
|---|---|
| Übergeordnetes Werk: |
volume:15 ; year:2013 ; number:1 ; pages:12-18 |
| Links: |
|---|
| Katalog-ID: |
DOAJ066452074 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ066452074 | ||
| 003 | DE-627 | ||
| 005 | 20230502124237.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2013 xx |||||o 00| ||rus c | ||
| 035 | |a (DE-627)DOAJ066452074 | ||
| 035 | |a (DE-599)DOAJbc3af08cf9de4677bdea45bc8f4ecbb2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 050 | 0 | |a RC254-282 | |
| 100 | 0 | |a PierFranco Conte |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current approach to adjuvant therapy for breast cancer (a review) |
| 264 | 1 | |c 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The current approaches to therapy for breast cancer (BC) are based on whether the major markers, such as estrogen receptors, progesterone receptors, and HER2-receptors, are present or absent. Scientific update suggests that subdividing BC into more minor, but distinct subgroups will be continued and treatment approaches will be improved. There is no question that screening and early diagnosis are important in improving treatment results and reducing BC mortality; however, there is increasing evidence for the precedence of adjuvant chemotherapy. Clinical trials show that incorporation of trastuzumab in adjuvant treatment regimens for HER2-positive BC improves substantially long-term results and reduces recurrence rates and the likelihood of a fatal outcome. Of particular interest is the fact that the drugs having different modes of action can produce double inhibition of HER2-receptor. Targeted therapy with trastuzumab in particular has changed dramatically the prognosis of the previously absolutely fatal variant of BC. Combination of targeted therapy will bring the era of personalized medicine closer. | ||
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a adjuvant therapy | |
| 650 | 4 | |a targeted therapy | |
| 650 | 4 | |a trastuzumab | |
| 653 | 0 | |a Neoplasms. Tumors. Oncology. Including cancer and carcinogens | |
| 700 | 0 | |a Valentina Guarneri |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Современная онкология |d IP Habib O.N., 2019 |g 15(2013), 1, Seite 12-18 |w (DE-627)1760605514 |x 18151442 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2013 |g number:1 |g pages:12-18 |
| 856 | 4 | 0 | |u https://doaj.org/article/bc3af08cf9de4677bdea45bc8f4ecbb2 |z kostenfrei |
| 856 | 4 | 0 | |u https://modernonco.orscience.ru/1815-1434/article/view/26879 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1815-1434 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1815-1442 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2013 |e 1 |h 12-18 | ||
| author_variant |
p c pc v g vg |
|---|---|
| matchkey_str |
article:18151442:2013----::urnapoctajvnteayobe |
| hierarchy_sort_str |
2013 |
| callnumber-subject-code |
RC |
| publishDate |
2013 |
| allfields |
(DE-627)DOAJ066452074 (DE-599)DOAJbc3af08cf9de4677bdea45bc8f4ecbb2 DE-627 ger DE-627 rakwb rus RC254-282 PierFranco Conte verfasserin aut Current approach to adjuvant therapy for breast cancer (a review) 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The current approaches to therapy for breast cancer (BC) are based on whether the major markers, such as estrogen receptors, progesterone receptors, and HER2-receptors, are present or absent. Scientific update suggests that subdividing BC into more minor, but distinct subgroups will be continued and treatment approaches will be improved. There is no question that screening and early diagnosis are important in improving treatment results and reducing BC mortality; however, there is increasing evidence for the precedence of adjuvant chemotherapy. Clinical trials show that incorporation of trastuzumab in adjuvant treatment regimens for HER2-positive BC improves substantially long-term results and reduces recurrence rates and the likelihood of a fatal outcome. Of particular interest is the fact that the drugs having different modes of action can produce double inhibition of HER2-receptor. Targeted therapy with trastuzumab in particular has changed dramatically the prognosis of the previously absolutely fatal variant of BC. Combination of targeted therapy will bring the era of personalized medicine closer. breast cancer adjuvant therapy targeted therapy trastuzumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens Valentina Guarneri verfasserin aut In Современная онкология IP Habib O.N., 2019 15(2013), 1, Seite 12-18 (DE-627)1760605514 18151442 nnns volume:15 year:2013 number:1 pages:12-18 https://doaj.org/article/bc3af08cf9de4677bdea45bc8f4ecbb2 kostenfrei https://modernonco.orscience.ru/1815-1434/article/view/26879 kostenfrei https://doaj.org/toc/1815-1434 Journal toc kostenfrei https://doaj.org/toc/1815-1442 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 15 2013 1 12-18 |
| spelling |
(DE-627)DOAJ066452074 (DE-599)DOAJbc3af08cf9de4677bdea45bc8f4ecbb2 DE-627 ger DE-627 rakwb rus RC254-282 PierFranco Conte verfasserin aut Current approach to adjuvant therapy for breast cancer (a review) 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The current approaches to therapy for breast cancer (BC) are based on whether the major markers, such as estrogen receptors, progesterone receptors, and HER2-receptors, are present or absent. Scientific update suggests that subdividing BC into more minor, but distinct subgroups will be continued and treatment approaches will be improved. There is no question that screening and early diagnosis are important in improving treatment results and reducing BC mortality; however, there is increasing evidence for the precedence of adjuvant chemotherapy. Clinical trials show that incorporation of trastuzumab in adjuvant treatment regimens for HER2-positive BC improves substantially long-term results and reduces recurrence rates and the likelihood of a fatal outcome. Of particular interest is the fact that the drugs having different modes of action can produce double inhibition of HER2-receptor. Targeted therapy with trastuzumab in particular has changed dramatically the prognosis of the previously absolutely fatal variant of BC. Combination of targeted therapy will bring the era of personalized medicine closer. breast cancer adjuvant therapy targeted therapy trastuzumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens Valentina Guarneri verfasserin aut In Современная онкология IP Habib O.N., 2019 15(2013), 1, Seite 12-18 (DE-627)1760605514 18151442 nnns volume:15 year:2013 number:1 pages:12-18 https://doaj.org/article/bc3af08cf9de4677bdea45bc8f4ecbb2 kostenfrei https://modernonco.orscience.ru/1815-1434/article/view/26879 kostenfrei https://doaj.org/toc/1815-1434 Journal toc kostenfrei https://doaj.org/toc/1815-1442 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 15 2013 1 12-18 |
| allfields_unstemmed |
(DE-627)DOAJ066452074 (DE-599)DOAJbc3af08cf9de4677bdea45bc8f4ecbb2 DE-627 ger DE-627 rakwb rus RC254-282 PierFranco Conte verfasserin aut Current approach to adjuvant therapy for breast cancer (a review) 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The current approaches to therapy for breast cancer (BC) are based on whether the major markers, such as estrogen receptors, progesterone receptors, and HER2-receptors, are present or absent. Scientific update suggests that subdividing BC into more minor, but distinct subgroups will be continued and treatment approaches will be improved. There is no question that screening and early diagnosis are important in improving treatment results and reducing BC mortality; however, there is increasing evidence for the precedence of adjuvant chemotherapy. Clinical trials show that incorporation of trastuzumab in adjuvant treatment regimens for HER2-positive BC improves substantially long-term results and reduces recurrence rates and the likelihood of a fatal outcome. Of particular interest is the fact that the drugs having different modes of action can produce double inhibition of HER2-receptor. Targeted therapy with trastuzumab in particular has changed dramatically the prognosis of the previously absolutely fatal variant of BC. Combination of targeted therapy will bring the era of personalized medicine closer. breast cancer adjuvant therapy targeted therapy trastuzumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens Valentina Guarneri verfasserin aut In Современная онкология IP Habib O.N., 2019 15(2013), 1, Seite 12-18 (DE-627)1760605514 18151442 nnns volume:15 year:2013 number:1 pages:12-18 https://doaj.org/article/bc3af08cf9de4677bdea45bc8f4ecbb2 kostenfrei https://modernonco.orscience.ru/1815-1434/article/view/26879 kostenfrei https://doaj.org/toc/1815-1434 Journal toc kostenfrei https://doaj.org/toc/1815-1442 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 15 2013 1 12-18 |
| allfieldsGer |
(DE-627)DOAJ066452074 (DE-599)DOAJbc3af08cf9de4677bdea45bc8f4ecbb2 DE-627 ger DE-627 rakwb rus RC254-282 PierFranco Conte verfasserin aut Current approach to adjuvant therapy for breast cancer (a review) 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The current approaches to therapy for breast cancer (BC) are based on whether the major markers, such as estrogen receptors, progesterone receptors, and HER2-receptors, are present or absent. Scientific update suggests that subdividing BC into more minor, but distinct subgroups will be continued and treatment approaches will be improved. There is no question that screening and early diagnosis are important in improving treatment results and reducing BC mortality; however, there is increasing evidence for the precedence of adjuvant chemotherapy. Clinical trials show that incorporation of trastuzumab in adjuvant treatment regimens for HER2-positive BC improves substantially long-term results and reduces recurrence rates and the likelihood of a fatal outcome. Of particular interest is the fact that the drugs having different modes of action can produce double inhibition of HER2-receptor. Targeted therapy with trastuzumab in particular has changed dramatically the prognosis of the previously absolutely fatal variant of BC. Combination of targeted therapy will bring the era of personalized medicine closer. breast cancer adjuvant therapy targeted therapy trastuzumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens Valentina Guarneri verfasserin aut In Современная онкология IP Habib O.N., 2019 15(2013), 1, Seite 12-18 (DE-627)1760605514 18151442 nnns volume:15 year:2013 number:1 pages:12-18 https://doaj.org/article/bc3af08cf9de4677bdea45bc8f4ecbb2 kostenfrei https://modernonco.orscience.ru/1815-1434/article/view/26879 kostenfrei https://doaj.org/toc/1815-1434 Journal toc kostenfrei https://doaj.org/toc/1815-1442 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 15 2013 1 12-18 |
| allfieldsSound |
(DE-627)DOAJ066452074 (DE-599)DOAJbc3af08cf9de4677bdea45bc8f4ecbb2 DE-627 ger DE-627 rakwb rus RC254-282 PierFranco Conte verfasserin aut Current approach to adjuvant therapy for breast cancer (a review) 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The current approaches to therapy for breast cancer (BC) are based on whether the major markers, such as estrogen receptors, progesterone receptors, and HER2-receptors, are present or absent. Scientific update suggests that subdividing BC into more minor, but distinct subgroups will be continued and treatment approaches will be improved. There is no question that screening and early diagnosis are important in improving treatment results and reducing BC mortality; however, there is increasing evidence for the precedence of adjuvant chemotherapy. Clinical trials show that incorporation of trastuzumab in adjuvant treatment regimens for HER2-positive BC improves substantially long-term results and reduces recurrence rates and the likelihood of a fatal outcome. Of particular interest is the fact that the drugs having different modes of action can produce double inhibition of HER2-receptor. Targeted therapy with trastuzumab in particular has changed dramatically the prognosis of the previously absolutely fatal variant of BC. Combination of targeted therapy will bring the era of personalized medicine closer. breast cancer adjuvant therapy targeted therapy trastuzumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens Valentina Guarneri verfasserin aut In Современная онкология IP Habib O.N., 2019 15(2013), 1, Seite 12-18 (DE-627)1760605514 18151442 nnns volume:15 year:2013 number:1 pages:12-18 https://doaj.org/article/bc3af08cf9de4677bdea45bc8f4ecbb2 kostenfrei https://modernonco.orscience.ru/1815-1434/article/view/26879 kostenfrei https://doaj.org/toc/1815-1434 Journal toc kostenfrei https://doaj.org/toc/1815-1442 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA AR 15 2013 1 12-18 |
| language |
Russian |
| source |
In Современная онкология 15(2013), 1, Seite 12-18 volume:15 year:2013 number:1 pages:12-18 |
| sourceStr |
In Современная онкология 15(2013), 1, Seite 12-18 volume:15 year:2013 number:1 pages:12-18 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
breast cancer adjuvant therapy targeted therapy trastuzumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| isfreeaccess_bool |
true |
| container_title |
Современная онкология |
| authorswithroles_txt_mv |
PierFranco Conte @@aut@@ Valentina Guarneri @@aut@@ |
| publishDateDaySort_date |
2013-01-01T00:00:00Z |
| hierarchy_top_id |
1760605514 |
| id |
DOAJ066452074 |
| language_de |
russisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ066452074</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502124237.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2013 xx |||||o 00| ||rus c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ066452074</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJbc3af08cf9de4677bdea45bc8f4ecbb2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">PierFranco Conte</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Current approach to adjuvant therapy for breast cancer (a review)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The current approaches to therapy for breast cancer (BC) are based on whether the major markers, such as estrogen receptors, progesterone receptors, and HER2-receptors, are present or absent. Scientific update suggests that subdividing BC into more minor, but distinct subgroups will be continued and treatment approaches will be improved. There is no question that screening and early diagnosis are important in improving treatment results and reducing BC mortality; however, there is increasing evidence for the precedence of adjuvant chemotherapy. Clinical trials show that incorporation of trastuzumab in adjuvant treatment regimens for HER2-positive BC improves substantially long-term results and reduces recurrence rates and the likelihood of a fatal outcome. Of particular interest is the fact that the drugs having different modes of action can produce double inhibition of HER2-receptor. Targeted therapy with trastuzumab in particular has changed dramatically the prognosis of the previously absolutely fatal variant of BC. Combination of targeted therapy will bring the era of personalized medicine closer.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">breast cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">adjuvant therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">targeted therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">trastuzumab</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Valentina Guarneri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Современная онкология</subfield><subfield code="d">IP Habib O.N., 2019</subfield><subfield code="g">15(2013), 1, Seite 12-18</subfield><subfield code="w">(DE-627)1760605514</subfield><subfield code="x">18151442</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:12-18</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/bc3af08cf9de4677bdea45bc8f4ecbb2</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://modernonco.orscience.ru/1815-1434/article/view/26879</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1815-1434</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1815-1442</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2013</subfield><subfield code="e">1</subfield><subfield code="h">12-18</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
PierFranco Conte |
| spellingShingle |
PierFranco Conte misc RC254-282 misc breast cancer misc adjuvant therapy misc targeted therapy misc trastuzumab misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens Current approach to adjuvant therapy for breast cancer (a review) |
| authorStr |
PierFranco Conte |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1760605514 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RC254-282 |
| illustrated |
Not Illustrated |
| issn |
18151442 |
| topic_title |
RC254-282 Current approach to adjuvant therapy for breast cancer (a review) breast cancer adjuvant therapy targeted therapy trastuzumab |
| topic |
misc RC254-282 misc breast cancer misc adjuvant therapy misc targeted therapy misc trastuzumab misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| topic_unstemmed |
misc RC254-282 misc breast cancer misc adjuvant therapy misc targeted therapy misc trastuzumab misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| topic_browse |
misc RC254-282 misc breast cancer misc adjuvant therapy misc targeted therapy misc trastuzumab misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Современная онкология |
| hierarchy_parent_id |
1760605514 |
| hierarchy_top_title |
Современная онкология |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1760605514 |
| title |
Current approach to adjuvant therapy for breast cancer (a review) |
| ctrlnum |
(DE-627)DOAJ066452074 (DE-599)DOAJbc3af08cf9de4677bdea45bc8f4ecbb2 |
| title_full |
Current approach to adjuvant therapy for breast cancer (a review) |
| author_sort |
PierFranco Conte |
| journal |
Современная онкология |
| journalStr |
Современная онкология |
| callnumber-first-code |
R |
| lang_code |
rus |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2013 |
| contenttype_str_mv |
txt |
| container_start_page |
12 |
| author_browse |
PierFranco Conte Valentina Guarneri |
| container_volume |
15 |
| class |
RC254-282 |
| format_se |
Elektronische Aufsätze |
| author-letter |
PierFranco Conte |
| author2-role |
verfasserin |
| title_sort |
current approach to adjuvant therapy for breast cancer (a review) |
| callnumber |
RC254-282 |
| title_auth |
Current approach to adjuvant therapy for breast cancer (a review) |
| abstract |
The current approaches to therapy for breast cancer (BC) are based on whether the major markers, such as estrogen receptors, progesterone receptors, and HER2-receptors, are present or absent. Scientific update suggests that subdividing BC into more minor, but distinct subgroups will be continued and treatment approaches will be improved. There is no question that screening and early diagnosis are important in improving treatment results and reducing BC mortality; however, there is increasing evidence for the precedence of adjuvant chemotherapy. Clinical trials show that incorporation of trastuzumab in adjuvant treatment regimens for HER2-positive BC improves substantially long-term results and reduces recurrence rates and the likelihood of a fatal outcome. Of particular interest is the fact that the drugs having different modes of action can produce double inhibition of HER2-receptor. Targeted therapy with trastuzumab in particular has changed dramatically the prognosis of the previously absolutely fatal variant of BC. Combination of targeted therapy will bring the era of personalized medicine closer. |
| abstractGer |
The current approaches to therapy for breast cancer (BC) are based on whether the major markers, such as estrogen receptors, progesterone receptors, and HER2-receptors, are present or absent. Scientific update suggests that subdividing BC into more minor, but distinct subgroups will be continued and treatment approaches will be improved. There is no question that screening and early diagnosis are important in improving treatment results and reducing BC mortality; however, there is increasing evidence for the precedence of adjuvant chemotherapy. Clinical trials show that incorporation of trastuzumab in adjuvant treatment regimens for HER2-positive BC improves substantially long-term results and reduces recurrence rates and the likelihood of a fatal outcome. Of particular interest is the fact that the drugs having different modes of action can produce double inhibition of HER2-receptor. Targeted therapy with trastuzumab in particular has changed dramatically the prognosis of the previously absolutely fatal variant of BC. Combination of targeted therapy will bring the era of personalized medicine closer. |
| abstract_unstemmed |
The current approaches to therapy for breast cancer (BC) are based on whether the major markers, such as estrogen receptors, progesterone receptors, and HER2-receptors, are present or absent. Scientific update suggests that subdividing BC into more minor, but distinct subgroups will be continued and treatment approaches will be improved. There is no question that screening and early diagnosis are important in improving treatment results and reducing BC mortality; however, there is increasing evidence for the precedence of adjuvant chemotherapy. Clinical trials show that incorporation of trastuzumab in adjuvant treatment regimens for HER2-positive BC improves substantially long-term results and reduces recurrence rates and the likelihood of a fatal outcome. Of particular interest is the fact that the drugs having different modes of action can produce double inhibition of HER2-receptor. Targeted therapy with trastuzumab in particular has changed dramatically the prognosis of the previously absolutely fatal variant of BC. Combination of targeted therapy will bring the era of personalized medicine closer. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA |
| container_issue |
1 |
| title_short |
Current approach to adjuvant therapy for breast cancer (a review) |
| url |
https://doaj.org/article/bc3af08cf9de4677bdea45bc8f4ecbb2 https://modernonco.orscience.ru/1815-1434/article/view/26879 https://doaj.org/toc/1815-1434 https://doaj.org/toc/1815-1442 |
| remote_bool |
true |
| author2 |
Valentina Guarneri |
| author2Str |
Valentina Guarneri |
| ppnlink |
1760605514 |
| callnumber-subject |
RC - Internal Medicine |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| callnumber-a |
RC254-282 |
| up_date |
2024-07-03T20:07:54.833Z |
| _version_ |
1803589805497384960 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ066452074</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502124237.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2013 xx |||||o 00| ||rus c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ066452074</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJbc3af08cf9de4677bdea45bc8f4ecbb2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">PierFranco Conte</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Current approach to adjuvant therapy for breast cancer (a review)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The current approaches to therapy for breast cancer (BC) are based on whether the major markers, such as estrogen receptors, progesterone receptors, and HER2-receptors, are present or absent. Scientific update suggests that subdividing BC into more minor, but distinct subgroups will be continued and treatment approaches will be improved. There is no question that screening and early diagnosis are important in improving treatment results and reducing BC mortality; however, there is increasing evidence for the precedence of adjuvant chemotherapy. Clinical trials show that incorporation of trastuzumab in adjuvant treatment regimens for HER2-positive BC improves substantially long-term results and reduces recurrence rates and the likelihood of a fatal outcome. Of particular interest is the fact that the drugs having different modes of action can produce double inhibition of HER2-receptor. Targeted therapy with trastuzumab in particular has changed dramatically the prognosis of the previously absolutely fatal variant of BC. Combination of targeted therapy will bring the era of personalized medicine closer.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">breast cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">adjuvant therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">targeted therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">trastuzumab</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Valentina Guarneri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Современная онкология</subfield><subfield code="d">IP Habib O.N., 2019</subfield><subfield code="g">15(2013), 1, Seite 12-18</subfield><subfield code="w">(DE-627)1760605514</subfield><subfield code="x">18151442</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:12-18</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/bc3af08cf9de4677bdea45bc8f4ecbb2</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://modernonco.orscience.ru/1815-1434/article/view/26879</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1815-1434</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1815-1442</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2013</subfield><subfield code="e">1</subfield><subfield code="h">12-18</subfield></datafield></record></collection>
|
| score |
7.4003096 |